Clinicopathological and Dermoscopic Baselines in Patients with Lynch Syndrome

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jan 8

PMID 36612110

Authors

Giovanni Paolino

Riccardo Pampena

Matteo Riccardo Di Nicola

Santo Raffaele Mercuri

Affiliations

Soon will be listed here.

Abstract

Despite the fact that Lynch Syndrome (LS) patients may also develop extra-colonic malignancies, research evaluating the association between LS and skin cancers is currently very limited. We performed a monocentric clinical and dermoscopic study involving 42 LS patients which referred to the Dermatology Unit for cutaneous screenings. In total, 22 patients showed a mutation in MLH1 and 17 patients a MSH2 mutation. Out of the entire cohort, 83% of LS patients showed brown hairs and 78% brown eyes, and the most frequent phototypes were III and II (respectively, 71.5% and 21%). A positive medical history for an internal malignancy was present in 36% of patients, with colon cancer as the most frequent malignancy in 60% of cases. A total of 853 cutaneous lesions have been analyzed: 47% of patients showed a total number of nevi > 10. The main observed dermoscopic features were a uniform reticular pattern (77% of patients), a mixed pattern (9% of patients) and a uniform dermal pattern (14% of patients). Eruptive cherry angiomas were present in 24% of cases, eruptive seborrheic keratosis in 26% and viral warts in 7% of cases; basal cell carcinoma was detected in 7% of cases. We have not found specific associations with specific skin manifestations, and the clinical and dermoscopic appearance of the pigmented lesions reflected the features present in the general population. To date, there are currently no guidelines for skin screening in LS patients. According to our study, there is insufficient evidence to ensure increased surveillance in LS patients; further studies with larger samples of patients are needed to better investigate dermatological and dermoscopic features in LS carriers.

References

Gandini S, Sera F, Cattaruzza M, Pasquini P, Abeni D, Boyle P . Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2004; 41(1):28-44. DOI: 10.1016/j.ejca.2004.10.015. View

Lynch H, Smyrk T . Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer. 1996; 78(6):1149-67. DOI: 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5. View

Lindor N . Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. Surg Oncol Clin N Am. 2009; 18(4):637-45. PMC: 3454516. DOI: 10.1016/j.soc.2009.07.003. View

Czako L, Tiszlavicz L, Takacs R, Baradnay G, Lonovics J, Cserni G . [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation]. Orv Hetil. 2005; 146(20):1009-16. View

Paolino G, Pampena R, Di Nicola M, Longo C, Rognone A, Zambelli S . Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers. Front Med (Lausanne). 2022; 9:863468. PMC: 9098930. DOI: 10.3389/fmed.2022.863468. View

Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F . Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009; 75(2):141-9. DOI: 10.1111/j.1399-0004.2008.01125.x. View

Donati M, Paolino G, Muscardin L, Panetta C, Donati P . Resolution of Benign and Malignant Sebaceous Neoplasms, in a Renal Transplant Patient Treated With Everolimus. Exp Clin Transplant. 2015; 15(1):100-102. DOI: 10.6002/ect.2014.0208. View

Donati P, Paolino G, Donati M, Panetta C . Adenocarcinoma of the cervix associated with a neuroendocrine small cell carcinoma of the cervix in the spectrum of Muir-Torre syndrome. Eur J Gynaecol Oncol. 2015; 36(2):213-5. View

Murphy H, Armstrong R, Cairns D, Greenhalgh K . Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation. Fam Cancer. 2008; 7(3):255-7. DOI: 10.1007/s10689-008-9183-y. View

10.

Samadder N, Smith K, Wong J, Thomas A, Hanson H, Boucher K . Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome. JAMA Oncol. 2017; 3(12):1697-1701. PMC: 5824265. DOI: 10.1001/jamaoncol.2017.0769. View

11.

Zalaudek I, Schmid K, Marghoob A, Scope A, Manzo M, Moscarella E . Frequency of dermoscopic nevus subtypes by age and body site: a cross-sectional study. Arch Dermatol. 2011; 147(6):663-70. DOI: 10.1001/archdermatol.2011.149. View

12.

DA Silva F, Petrolini de Oliveira L, Santos E, Nakagawa W, Junior S, Valentin M . Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer. 2010; 9(4):563-70. DOI: 10.1007/s10689-010-9373-2. View

13.

Lynch H, Lynch P, Pester J, Fusaro R . The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med. 1981; 141(5):607-11. View

14.

Bosetti C, Traini E, Alam T, Allen C, Carreras G, Compton K . National burden of cancer in Italy, 1990-2017: a systematic analysis for the global burden of disease study 2017. Sci Rep. 2020; 10(1):22099. PMC: 7744506. DOI: 10.1038/s41598-020-79176-3. View

15.

Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans D . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2015; 66(3):464-472. PMC: 5534760. DOI: 10.1136/gutjnl-2015-309675. View

16.

Zalaudek I, Grinschgl S, Argenziano G, Marghoob A, Blum A, Richtig E . Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi. Br J Dermatol. 2006; 154(2):299-304. DOI: 10.1111/j.1365-2133.2005.06973.x. View

17.

Hitchins M, Ward R . Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet. 2009; 46(12):793-802. DOI: 10.1136/jmg.2009.068122. View

18.

Goecke T, Schulmann K, Engel C, Holinski-Feder E, Pagenstecher C, Schackert H . Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol. 2006; 24(26):4285-92. DOI: 10.1200/JCO.2005.03.7333. View